Human Pharma Services
CanCog offers a wide range of services that provide guidance and proof-of-concept through various aspects of the preclinical development phase of new compounds. These include:
- Canine models for the evaluation of lead compounds for cognitive disorders associated with age and neurodegeneration, such as Alzheimer's disease and mild cognitive impairment
- Neuroprotective screens using histological and imaging procedures
- Non-cognitive behavioral screens, including day-night activity, behavioral activity and exploratory behavior,
- Rodent models for cognition, schizophrenia, depression and anxiety
- Rodent and primate screens of therapeutics for human movement-disorders, such as Parkinson's disease
- Brain imaging (MRI and PET)
- Canine and rodent models for assessment of appetite modifying therapeutics
All of these services are available using GLP-compatible practices.